O'Gorman Cedric's Form 4 filing
Relmada Therapeutics, Inc. (RLMD) · filed May 24, 2023
- Accession no.
- 0001213900-23-042554
- Filed
- May 24, 2023
- Trade date
- May 23, 2023
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $31.8K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| O'Gorman CedricCIK 0001962179 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 23, 2023 | Common Stock | PPurchaseAcquired | +10,000 | $3.18F2 | +$31,800 | 10,121 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Purchase prices range from $3.135 to $3.2096 per share, inclusive.
Referenced by the price of 1 transaction in Table I.